Pacific Biosciences of California Inc. has completed the sale of select intellectual property and other assets related to its short-read DNA sequencing technology and associated clustering, sequencing reagent, and detection technologies to Illumina, Inc. The deal brought PacBio $48.1 million in net cash proceeds, with Illumina also assuming certain liabilities and granting a non-exclusive license for certain intellectual property back to PacBio. The transaction closed on January 30, 2026. According to PacBio, this move allows the company to focus on its long-read sequencing platform and accelerate the development of its SPRQ-Nx chemistry for global launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Biosciences of California Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9646735) on February 02, 2026, and is solely responsible for the information contained therein.